Liquidia Corporation (LQDA)
Liquidia Corporation operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Morrisville, NC, US. The stock last traded at $84.20, down 4.37% on the session, giving a market capitalisation of $7.49B. On trailing twelve-month figures it carries a trailing P/E of 53.66, a net margin of 30.7%. Its beta of 0.57 implies it has historically moved less than the broad market.
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
Liquidia Corporation is most often compared with the following Healthcare names: